URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
https://doi.org/10.20996/1819-6446-2008-4-3-65-71
Abstract
Aim. To compare urodynamic effects of beta-blockers with different selectivity (propranolol, metoprolol, nebivolol) in patients with arterial hypertension (HT) and concomitant benign prostatic hyperplasia (BPH).
Material and methods. 32 patients (aged 67,5 y.o. in average) with HT of 1-2 stages were involved in the study. All patients had BPH (prostate volume >40 sm3 , increase of residual urine volume) with moderate or severe low urinary tract symptoms (IPSS 8-25) and reduction of maximum urine flow rate to 5-13 ml/s. The urodynamic effect of beta-blockers was estimated by changes of urination frequency and uroflowmetry indices after single taking and 14-day therapy.
Results. Propranolol and metoprolol led to aggravation of urination disorders. Nebivolol resulted in soft urodilating and urostimulating effects. It led to urination improvement and reduced a risk of urodynamic disorders.
Conclusion. Urodynamic effects of cardiovascular drugs should be considered by practitioners especially in treatment of elderly patients.
About the Authors
M. P. Savenkov
Russian State Medical University, Moscow
Russian Federation
Russian Federation
A. S. Volkova
Russian State Medical University, Moscow
Russian Federation
Russian Federation
A. V. Kirienko
Russian State Medical University, Moscow
Russian Federation
Russian Federation
S. N. Ivanov
Russian State Medical University, Moscow
Russian Federation
Russian Federation
S. V. Ivanov
Russian State Medical University, Moscow
Russian Federation
Russian Federation
References
1. Рабочая группа Европейского общества кардиологов по бета-блокаторам. Документ о соглашении экспертов по блокаторам β-ад- ренергических рецепторов. Кардиоваск тер профилакт 2005; 4(1):99-123.
2. Michel M.C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147 Suppl 2: S88–S119.
3. Furuta A., Thomas C.A., Higaki M. et al. The promise of beta3-adrenoceptor agonists to treat the overactive bladder. Urol Clin North Am 2006;33(4):539-43.
4. Andersson K.E., Wein A.J. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004; 56(4):581–631
5. Andersson K.E., Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84(3):935-86.
6. Sein Anand J, Chodorowski Z, Hajduk A.. Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment. Przegl Lek 2005; 62(6):522-3.
7. Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М.: Вече; 2003.
8. Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕДпресс-информ; 2003.
9. Srikrishna S., Robinson D., Cardozo L., Vella M. Management of overactive bladder syndrome. Postgrad Med J 2007;83(981):481-6.
10. Kuroedov A., Cosentino F., Luscher T.F. Pharmacological mechanisms of clinically favorable properties of selective beta1-adrenoceptor antagonist nebivolol. Cardiovasc Drug Rev 2004;22(3):155–168.
11. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004;1:17-32.
12. Мазо Е.Б., Кривобородов Г.Г., Суханов С.В. Методы исследования уродинамики нижних мочевых путей. Методические рекомендации. М., 1998
13. Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б., Данилов В.В., Виш- невский А.Е. Урофлоуметрия. М., 2004.
14. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52.
15. Tsujii T., Azuma H., Yamaguchi T., Oshima H. A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J Pharmacol 1992;107(3): 803- 6.
16. Li G., Li K., Li Z., Wang P. Age-dependent changes in beta-adrenoceptor function in human detrusors and possible mechanisms. Chin Med J (Engl) 2003;116(10):1511-15.
17. Nomiya M., Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170(2 Pt 1):649-53.
18. Flather M.D., Shibata M.C., Coats A.J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215–40.
Review
For citations:
Savenkov M.P., Volkova A.S., Kirienko A.V., Ivanov S.N., Ivanov S.V. URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES. Rational Pharmacotherapy in Cardiology. 2008;4(3):65-71. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-3-65-71
Views:
13074
Email this article 